Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
ID Week: highlights uit de Late Breaker-sessies
okt 2021 | Bacteriële infecties, HIV, Tuberculose, Vaccinatie, Virale infecties